Literature DB >> 33830520

SARS-CoV-2 show no infectivity at later stages in a prolonged COVID-19 patient despite positivity in RNA testing.

Xiu-Feng Wan1,2,3,4,5, Cynthia Y Tang1,2,3,5, Detlef Ritter6, Yang Wang1,2,3, Tao Li7, Karen Segovia1,2,3, Martina Kosikova8, Marc Johnson2, Hyung J Kwon8, Hang Xie8, Richard D Hammer6, Jane A McElroy9, Aws Hamid10, Natalie D Collins7, Jun Hang7, Simone Camp6.   

Abstract

Inpatient coronavirus disease 2019 (COVID-19) cases present enormous costs to patients and health systems in the United States. Many hospitalized patients may continue testing COVID-19 positive even after the resolution of symptoms. Thus, a pressing concern for clinicians is the safety of discharging these asymptomatic patients if they have any remaining infectivity. This case report explores the viral viability in a patient with persistent COVID-19 over the course of a 2-month hospitalization. Positive nasopharyngeal swab samples were collected and isolated in the laboratory and analyzed by quantitative reverse-transcription polymerase chain reactions (qRT-PCR), and serology was tested for neutralizing antibodies throughout the hospitalization period. The patient experienced waning symptoms by hospital day 40 and had no viable virus growth by hospital day 41, suggesting no risk of infectivity, despite positive RT-PCR results which prolonged his hospital stay. Notably, this case showed infectivity for at least 24 days after disease onset, which is longer than the discontinuation of transmission-based precautions recommended by the Center for Disease Control and Prevention. Thus, our findings suggest that the timeline for discontinuing transmission-based precautions may need to be extended for patients with severe and prolonged COVID-19 disease. Additional large-scale studies are needed to draw definitive conclusions on the appropriate clinical management for these patients. ​.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; inpatients; patient discharge; real-time polymerase chain reaction

Year:  2021        PMID: 33830520     DOI: 10.1002/jmv.27001

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

Review 1.  Antigenic characterization of influenza and SARS-CoV-2 viruses.

Authors:  Yang Wang; Cynthia Y Tang; Xiu-Feng Wan
Journal:  Anal Bioanal Chem       Date:  2021-12-14       Impact factor: 4.142

2.  Prolonged SARS-CoV-2 Positivity in Immunocompetent Patients: Virus Isolation, Genomic Integrity, and Transmission Risk.

Authors:  Terezinha Marta Pereira Pinto Castiñeiras; Luciana Jesus da Costa; Isabela de Carvalho Leitão; Pedro Telles Calil; Rafael Mello Galliez; Filipe Romero Rebello Moreira; Diana Mariani; Anna Carla Pinto Castiñeiras; Gustavo Peixoto Duarte da Silva; Richard Araújo Maia; Isadora Alonso Corrêa; Fábio Luís Lima Monteiro; Marcos Romário Matos de Souza; Cássia Cristina Alves Gonçalves; Luiza Mendonça Higa; Liane de Jesus Ribeiro; Vinicius Wakoff Pereira Fonseca; Victoria Cortes Bastos; Carolina Moreira Voloch; Débora Souza Faffe; Orlando da Costa Ferreira; Amilcar Tanuri
Journal:  Microbiol Spectr       Date:  2021-11-17

3.  Persistence of infectious SARS-CoV-2 particles for up to 37 days in patients with mild COVID-19.

Authors:  Tobias Zahn; Ines Mhedhbi; Sascha Hein; Jan Raupach; Csaba Miskey; Younes Husria; Kathrin Bayanga; Detlef Bartel; Stefan Vieths; Zoltan Ivics; Doris Oberle; Brigitte Keller-Stanislawski; Marie-Luise Herrlein; Thorsten Jürgen Maier; Eberhard Hildt
Journal:  Allergy       Date:  2021-10-24       Impact factor: 14.710

4.  Duration of SARS-CoV-2 shedding and infectivity in the working age population: a systematic review and meta-analysis.

Authors:  Alborz Rahmani; Guglielmo Dini; Veruscka Leso; Alfredo Montecucco; Bruno Kusznir Vitturi; Ivo Iavicoli; Paolo Durando
Journal:  Med Lav       Date:  2022-04-26       Impact factor: 2.244

Review 5.  Determining SARS-CoV-2 non-infectivity state-A brief overview.

Authors:  Siggeir F Brynjolfsson; Hildur Sigurgrimsdottir; Olafur Gudlaugsson; Mar Kristjansson; Karl G Kristinsson; Bjorn R Ludviksson
Journal:  Front Public Health       Date:  2022-08-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.